Forward catalyst · AMGN

tarlatamab

Sponsor Amgen INC · listed as AMGN

READOUT Phase 3 Confidence: medium Source: clinicaltrials

tarlatamab is a clinical-stage drug asset sponsored by Amgen INC, listed as AMGN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jul 5, 2027 (day precision, medium confidence), tied to trial NCT06211036. The asset is in Phase 3 and currently active not recruiting, studied in Extensive-Stage Small-Cell Lung Cancer. It appears across 5 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2027-07-05

As disclosedJul 5, 2027

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT06211036

PhasePHASE3

StatusACTIVE_NOT_RECRUITING

Lead sponsorAmgen

Listed asAMGN

Condition(s)Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More AMGN catalysts